RCM
UTHR icon

Riverhead Capital Management’s United Therapeutics UTHR Stock Holding History

Riverhead Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$961K Sell
12,050
-9,200
-43% -$741K 0.04% 501
2019
Q2 		$1.66M Sell
21,250
-10,500
-33% -$982K 0.06% 378
2019
Q1 		$3.73M Sell
31,750
-20,600
-39% -$2.4M 0.15% 190
2018
Q4 		$5.7M Buy
52,350
+3,600
+7% +$417K 0.26% 92
2018
Q3 		$6.23M Buy
48,750
+12,850
+36% +$1.59M 0.23% 120
2018
Q2 		$4.06M Buy
35,900
+7,500
+26% +$824K 0.16% 179
2018
Q1 		$3.19M Buy
28,400
+20,900
+279% +$2.66M 0.13% 209
2017
Q4 		$1.11M Buy
7,500
+2,870
+62% +$365K 0.05% 404
2017
Q3 		$543K Sell
4,630
-14,995
-76% -$1.91M 0.03% 576
2017
Q2 		$2.55M Sell
19,625
-6,661
-25% -$831K 0.13% 207
2017
Q1 		$3.56M Sell
26,286
-11,114
-30% -$1.68M 0.2% 156
2016
Q4 		$5.36M Buy
37,400
+5,119
+16% +$654K 0.33% 67
2016
Q3 		$3.81M Buy
32,281
+19,301
+149% +$2.32M 0.25% 120
2016
Q2 		$219K Sell
12,980
-47,895
-79% -$5.34M 0.01% 868
2016
Q1 		$6.78M Buy
60,875
+34,883
+134% +$4.41M 0.1% 273
2015
Q4 		$4.07M Buy
25,992
+23,492
+940% +$3.42M 0.06% 375
2015
Q3 		$328K Buy
+2,500
New +$401K 0.01% 618

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Riverhead Capital Management's UTHR Position: Q3 2019 in Review

Riverhead Capital Management reduced its United Therapeutics (UTHR) stake by 43% in Q3 2019, selling an estimated $741K and leaving 12,050 shares worth $961K. The position accounts for 0.04% of the portfolio, ranked #501.

Riverhead Capital Management first reported a position in UTHR in Q3 2015 and has held it in 17 quarters since. The position peaked at $6.78M in Q1 2016. 302 funds tracked by Wall St. Rank hold UTHR as of Q3 2019.

  • Riverhead Capital Management held 12,050 shares of United Therapeutics worth $961K as of Q3 2019.
  • Riverhead Capital Management sold 9,200 United Therapeutics shares in Q3 2019, an estimated $741K.
  • United Therapeutics made up 0.04% of Riverhead Capital Management's portfolio in Q3 2019, its #501 holding.
  • Riverhead Capital Management first reported a position in United Therapeutics in Q3 2015 and has held it in 17 quarters since.
  • Riverhead Capital Management's United Therapeutics position peaked at $6.78M in Q1 2016.
  • 302 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2019.

Based on Riverhead Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.